Drug intelligence / Profile preview

DES-9384

Development stage: Unknown
Lead developer: D. E. Shaw Research
Modality: Small Molecules

Overview

DES-9384 is a small molecule inhibitor of the transient receptor potential cation channel subfamily A member 1 (TRPA1). It was developed by D.E. Shaw Research and is being investigated for its potential to treat conditions involving respiratory and inflammatory diseases. The drug specifically targets TRPA1, a protein implicated in chronic cough, rheumatoid arthritis, various types of pain including arthritic pain, diabetic neuropathy, and chronic lower back pain. As of mid-2025, DES-9384 has reached Phase 1 clinical trials for several indications related to immune system diseases, nervous system diseases, and endocrinology/metabolic disorders[1][2][3][5].

Targets

TRPA1 (Transient receptor potential cation channel subfamily A member 1)

Beyond the preview

Go deeper on DES-9384.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DES-9384.

Explore the full profile